Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors

The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need...

Descripción completa

Detalles Bibliográficos
Autores principales: Goossens, Martine, Pauwels, Katia, Willemarck, Nicolas, Breyer, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031919/
https://www.ncbi.nlm.nih.gov/pubmed/24397528
http://dx.doi.org/10.2174/156652321306140103221941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031919/
https://www.ncbi.nlm.nih.gov/pubmed/24397528
http://dx.doi.org/10.2174/156652321306140103221941

Ejemplares similares